LIFEVANTAGE CORP Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

LIFEVANTAGE CORP (LFVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 126.00% for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-08.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2012-11-08

LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2012-09-30 was 126.00%, a 8.03% decline year-over-year.
LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2011-09-30 was 137.00%.

Period end	Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month
2012-09-30	126.00% 10-Q · filed 2012-11-08
2011-09-30	137.00% 10-Q · filed 2012-11-08

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Adicet Bio, Inc. (ACET)	United States	$0.078B	-0.81
Valion Bio, Inc. (VBIO)	United States	$0.077B
MAIA Biotechnology, Inc. (MAIA)	United States	$0.077B	-2.30
iBio, Inc. (IBIO)	United States	$0.077B	-2.94
Verrica Pharmaceuticals Inc. (VRCA)	United States	$0.076B	-3.39
OS Therapies Inc (OSTX)	United States	$0.076B	-2.17
Gain Therapeutics, Inc. (GANX)	United States	$0.080B	-4.40
Aldeyra Therapeutics, Inc. (ALDX)	United States	$0.074B	-5.57
Cingulate Inc. (CING)	United States	$0.073B	-2.64
Spero Therapeutics, Inc. (SPRO)	United States	$0.073B	17.41